

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 January 2025 (16.01.2025)



(10) International Publication Number
WO 2025/012080 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C12N 15/13 (2006.01)
A61P 35/02 (2006.01) G01N 33/577 (2006.01)
A61K 47/68 (2017.01)

(21) International Application Number:

PCT/EP2024/068866

(22) International Filing Date:

04 July 2024 (04.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23185199.9 13 July 2023 (13.07.2023) EP

(71) Applicant:

CHRISTIAN-AL-BRECHTS-UNIVERSITÄT ZU KIEL [DE/DE]; Christian-Albrechts-Platz 4, 24118 Kiel (DE).

(72) Inventors: **KELLNER, Christian**; c/o Abt. für Trans-

fusionsmedizin, Zelltherapeutika und Hämostaseologie, Klinikum der Universität München, LMU München, Max-Lebsche-Platz 32, 81377 München (DE). **PEIPP, Matthias**; c/o Sektion für Antikörperbasierte Immuntherapie, Klinik für Innere Medizin II, Rosalind-Franklin-Str. 12, 24105 Kiel (DE). **KROHN, Steffen**; c/o Sektion für Antikörperbasierte Immuntherapie, Klinik für Innere Medizin II, Rosalind-Franklin-Str. 12, 24105 Kiel (DE). **KLAUSZ, Katja**; c/o Sektion für Antikörperbasierte Immuntherapie, Klinik für Innere Medizin II, Rosalind-Franklin-Str. 12, 24105 Kiel (DE). **WINTERBERG, Dorothee**; c/o Sektion für Antikörperbasierte Immuntherapie, Klinik für Innere Medizin II, Rosalind-Franklin-Str. 12, 24105 Kiel (DE). **GEHLERT, Carina Lynn**; c/o Sektion für Antikörperbasierte Immuntherapie, Klinik für Innere Medizin II, Rosalind-Franklin-Str. 12, 24105 Kiel (DE). **BOJE, Ammelie Svea**; c/o Sektion für Antikörperbasierte Immuntherapie, Klinik für Innere Medizin II, Rosalind-Franklin-Str. 12, 24105 Kiel (DE). **GRAMATZKI, Martin**; c/o Sektion für Stammzell- und Immuntherapie, Dr. Mildred-Scheel-Haus, Arnold-Heller-Str. 3, 24105 Kiel (DE).

(74) Agent: **VOSSIUS & PARTNER PATENTANWÄLTE**

RECHTSANWÄLTE MBB; Siebertstraße 3, 81675 München (DE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HUMANIZED ANTI-CD7 ANTIBODY

(57) Abstract: The present invention relates to an antibody binding to CD7, wherein the antibody comprises the V_H region determined by the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence being at least 90%, preferably at least 95% identical thereto; and the V_L region determined by the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence being at least 90%, preferably at least 95% identical thereto, provided that the three CDRs of the V_H region are determined by the amino acid sequences of SEQ ID NOS 3 to 5, and the three CDRs of the V_L region are determined by the amino acid sequences of SEQ ID NOS 6 to 8 (SEQ ID NO: 7 "AAS").

WO 2025/012080 A1